Status:
COMPLETED
Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
Lead Sponsor:
Rabin Medical Center
Conditions:
Obesity-induced Hyperfiltration
Eligibility:
MALE
18-55 years
Phase:
NA
Brief Summary
Background: Obesity is associated with a high prevalence of chronic kidney disease.The glomerular hyperfiltration associated with obesity may play a role in the pathogenesis of obesity associated chr...
Detailed Description
BACKGROUND Almost half of the causes of death in the industrial world are due to cardio-vascular (CV) disease. Two of the main risk factors for CV disease have become much more prevalent during the la...
Eligibility Criteria
Inclusion
- 15 obese men (BMI\>30), aged 18 to 55, with glomerular hyperfiltration (creatinine clearance\>130 ml/min)) and 10 normal body weight men (BMI\<25), aged 18 to 55.
Exclusion
- Heart failure, CKD, COPD
- Known allergy to furosemide, acetazolamide, inulin or amino-hippurate
- Pharmacologic treatment for hypertension, cardiac disease, diabetes mellitus
- Treatment with corticosteroids, antiepileptics or NSAID
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01146288
Start Date
July 1 2010
End Date
May 1 2014
Last Update
June 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Israel